AstraZeneca reports baxdrostat met primary, secondary endpoints in Phase 3 trial

Positive full results from the BaxHTN Phase III trial showed baxdrostat demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure at two doses compared with placebo at 12 weeks. Results were seen in patients with hard-to-control hypertension who received baxdrostat or placebo on top of standard of care, AstraZeneca (AZN) announced. These data were presented in a Hot Line session at the European Society of Cardiology Congress 2025 and also simultaneously published in the New England Journal of Medicine. Baxdrostat met the primary and all secondary endpoints in the BaxHTN Phase III trial, delivering meaningful and sustained blood pressure reductions in patients with hard-to-control hypertension. At week 12, the absolute reduction from baseline in mean seated SBP was 15.7 mmHg and placebo-adjusted reduction was 9.8 mmHg for the 2mg dose. For the 1mg dose, the absolute reduction from baseline was 14.5 mmHg and placebo-adjusted reduction was 8.7 mmHg. The reduction in mean seated SBP with placebo was 5.8 mmHg. Results were consistent across both uncontrolled and treatment-resistant subgroups. Baxdrostat was generally well tolerated with no unanticipated safety findings, and low rates of confirmed hyperkalaemia compared with placebo, the company stated.